Net sales of insulin medications of Novo Nordisk in Greater China 2022, by type

Published by
Wenyi Zhang,
Sep 25, 2023
In 2022, the Danish pharmaceutical company Novo Nordisk reported a net sales of over 4.9 billion Danish kroner from its premix insulin in Greater China. Diabetes care drug is the key product of the firm, generating over 15.2 billion net sales in the region that year.

Net sales of insulin medications of Novo Nordisk in Greater China in 2022, by type (in million DKK)

© Statista 2023
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

February 2023

Region

China, Taiwan, Hong Kong

Survey time period

2022

Supplementary notes

One Danish kroner equals approximately 0.14 U.S. dollars and 0.13 euros (as of September 2023).

Citation formats
Statista Accounts: Access All Statistics. Starting from $1,788 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$149 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Other statistics that may interest you

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Statistics on

About the industry

10

About the region

10

Selected statistics

10

Other regions

10

Related statistics

10

Further related statistics

10

Further Content: You might find this interesting as well

Statistics

Topics

Novo NordiskGlobal pharmaceutical industryPharmaceutical industry in the U.S.DiabetesDiabetes in China
Statista Accounts: Access All Statistics. Starting from $1,788 USD / Year
Learn more about how Statista can support your business.
Menu